North Carolina 2025-2026 Regular Session

North Carolina House Bill H824

Introduced
4/8/25  

Caption

Expand Treatment Access/Opioid Use Disorder

Impact

The bill proposes significant amendments to the state's General Statutes, effectively mandating that health benefit plans cover a variety of healthcare services provided by pharmacists, including the dispensing of medication and administration of treatments such as vaccines. By ensuring that pharmacists are included in insurance networks on equal footing with other healthcare providers, the bill seeks to enhance the systemic response to opioid-related challenges. The effective date for these amendments is set for October 1, 2025, which gives insurers time to adjust their policies and coverage criteria accordingly.

Summary

House Bill 824, titled 'Expand Treatment Access/Opioid Use Disorder', is designed to improve access to treatment for opioid use disorder and overdose in North Carolina. The bill aims to update health benefit plan coverage and reimbursement protocols for medications related to overdose and substance use disorders. It emphasizes the need for equitable insurance coverage for services provided by pharmacists, recognizing their role in managing opioid use treatment by allowing pharmacies to offer necessary services under various health benefit plans. This legislative change reflects a broader commitment to addressing the opioid crisis through a more inclusive healthcare model.

Sentiment

Overall sentiment surrounding HB 824 is largely positive among healthcare advocates and legislators focused on reducing the stigma associated with substance use disorders. Supporters believe that enhancing treatment access is critical in combating the opioid epidemic, and they commend the efforts to create parity in health coverage. However, some concerns have been raised regarding potential implementation challenges and the consequences for insurers in adapting to the new requirements. The emphasis on improving access through pharmacists is viewed favorably, yet the practicality of integrating these changes into existing insurance frameworks remains a point of discussion.

Contention

As with many healthcare-related legislative efforts, HB 824 faces some contention, particularly regarding the balance between expanding access and managing costs. Insurers may raise concerns about the financial implications of mandated coverage expansions and the operational adjustments necessary to comply with new regulations. Furthermore, there may be debates about the adequacy of current training and resources available to pharmacists to provide these expanded services effectively. The push for equity in treatment access also raises questions about ensuring that mental health and substance use disorder treatments receive the same focus and funding as physical health treatments.

Companion Bills

No companion bills found.

Similar Bills

TX SB594

Relating to the regulation of prescriptions for controlled substances, including certain procedures applicable to electronic prescriptions for Schedule II controlled substances.

TX HB2246

Relating to certain procedures applicable to electronic prescriptions for Schedule II controlled substances.

TX HB2766

Relating to electronic and other controlled substance prescriptions under the Texas Controlled Substances Act; authorizing a fee.

TX HB2174

Relating to controlled substance prescriptions and reimbursement for treatment for certain substance use disorders; authorizing a fee.

TX SB1233

Relating to controlled substance prescriptions under the Texas Controlled Substances Act; authorizing a fee.

AZ HB2291

Opioids; containers; labeling; requirements; repeal

TX HB2859

Relating to prescriber and dispenser reporting and access to patient prescription information under the Texas Controlled Substances Act.

NJ A1853

Requires all prescriptions be transmitted electronically, subject to certain exceptions.